Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Allan F who wrote (3089)	3/26/1998 6:32:00 PM
From: Jacques Chitte	Read Replies (1) \| Respond to of 7041

I think that unlikely. The delay probably stems from problems with the clinical results. Many a good honest compound has fallen by the wayside due to inept clinical experimentation. I don't think phentolamine is an outright fraud. I do think it stands at best a mediocre chance of getting approved for the US market. Its chances of being a commercial success are worse. Adrenergic antagonists, notably alpha-two blockers, for erectile dysfunction are an old old idea, and if phentolamine were genuinely good, it would have already been done by the big boys. Imho.